ORIGINAL RESEARCH



# **Exercise Intervention as a Therapy in Patients** with Diabetes Mellitus and Sarcopenia: A Meta-Analysis

Siyao Gao  $\cdot$  Ling Yu  $\cdot$  Guozhong Yi  $\cdot$  Tong Li  $\cdot$  Zhenyin Chen  $\cdot$  Jiawang Ding

Received: April 20, 2022 / Accepted: May 12, 2022 / Published online: June 1, 2022  $\circledcirc$  The Author(s) 2022

### ABSTRACT

*Introduction*: Sarcopenia is defined as a progressive and generalized muscle disorder that involves accelerated loss of muscle mass and impaired function. It is believed to influence the ability to carry out daily activities, muscle strength, and physical capacity in the elderly. Studies have shown that sarcopenia has been implicated as both a cause and a consequence of diabetes mellitus. In this analysis, we aimed to systematically show the impact of exercise

S. Gao · L. Yu ( $\boxtimes$ ) · G. Yi · T. Li · Z. Chen Department of Physical Education, Central South University, Changsha 410083, Hunan, People's Republic of China e-mail: yulingcsu@163.com

S. Gao e-mail: gaosiyao@csu.edu.cn

G. Yi e-mail: 26987798@qq.com

T. Li e-mail: 2438357594@qq.com

Z. Chen e-mail: 472473468@qq.com

J. Ding

Department of Internal Medicine, Beijing Chaoyang Hospital, Chaoyang, Beijing 100020, People's Republic of China e-mail: liuhaomd2013@163.com intervention as a therapy for patients with diabetes mellitus and sarcopenia.

*Methods*: Electronic databases, including PubMed, EMBASE, Web of Science, and the Cochrane database, were searched from November to December 2021 for publications based on exercise intervention in patients with sarcopenia. After the selection of studies for this analysis, patients with diabetes mellitus were retrieved. Since dichotomous data including mean and standard deviation were reported, weighted mean difference (MD) with 95% confidence intervals (CI) were used to represent the data following analysis.

Results: A total of 431 participants with diabetes mellitus and sarcopenia were included in this meta-analysis. A statistical analysis was carried out on patients with diabetes mellitus who were assigned to the exercise intervention group. Our analysis showed that "sit-tostand test" and "timed up and go" were significantly in favor of exercise intervention: MD -1.57, 95% confidence interval (CI) -2.26to -0.87 (*P* = 0.0001) versus MD -0.61, 95% CI -1.21 to -0.01 (*P* = 0.05), respectively. Handgrip strength, walking speed and leg strength were also assessed. Another statistical analysis was carried out, this time on patients with diabetes mellitus and sarcopenia who were not assigned to an exercise intervention.

The results showed no significant difference among sit-to-stand test, timed up and go, handgrip strength, and leg strength.

*Conclusion*: Exercise intervention significantly improved the time taken to stand up from a sitting position, and to "stand up and go" in patients with diabetes mellitus and sarcopenia. Therefore, exercise intervention should be considered a relevant therapy for such patients.

**Keywords:** Exercise intervention; Diabetes mellitus; Sarcopenia; Frail elderly; Diabetes therapy

### **Key Summary Points**

Sarcopenia is defined as a progressive and generalized muscle disorder that involves accelerated loss of muscle mass and impaired function.

It is believed to influence the ability to carry out daily activities, muscle strength, and physical capacity in the elderly.

Studies have shown that sarcopenia has been implicated as both a cause and a consequence of diabetes mellitus.

In this analysis, we aimed to systematically show the impact of exercise intervention as a therapy for patients with diabetes mellitus and sarcopenia.

Exercise intervention significantly improved the time taken to stand up from a sitting position, and to "stand up and go" in patients with diabetes mellitus and sarcopenia.

Therefore, exercise intervention should be considered a relevant therapy for such patients.

## INTRODUCTION

Sarcopenia is defined as a progressive and generalized muscle disorder that involves accelerated loss of muscle mass and impaired function that could result in serious adverse outcomes, including functional decline and physical incapability, falls and fractures, frailty, and mortality [1]. With advanced age, there is an inevitable decline in muscle mass, showing that sarcopenia usually develops with increased age [2]. Sarcopenia is believed to influence the ability to carry out daily activities [3], muscle strength, and physical capacity in the elderly [4]. It has been estimated that 5-13% of the elderly population aged between 60 and 70 years are affected by sarcopenia, and this number increases up to 11-50% among elderly people above 80 years of age [4]. Sarcopenia is one of the main reasons for loss of muscle mass. Several tests, including the short physical performance battery test, the timed-up-and-go test, and the chair-power climbing test could be used to assess muscle strength in patients with sarcopenia. Preventing or decreasing the intensity of sarcopenia could prevent further problems related to physical capacity [5]. Patients with diabetes mellitus are at greater risk of such physical incapability due to the impact of this chronic disease on their health.

Studies have shown that sarcopenia has been implicated as both a cause and a consequence of diabetes mellitus [6]. This chronic disease is characterized by insulin resistance, oxidative stress, increased advanced glycation end products, and a proinflammatory phenotype, which could result in macro- and microvascular complications and further interfere with normal cellular functioning and cause cell death, potentially leading to loss of skeletal muscle mass, strength, and function, resulting in sarcopenia [7]. Conversely, low muscle mass and function in sarcopenia could lead to weaker glucose disposal and reduced metabolic rate and physical activity, all of which might place elderly with sarcopenia at higher risk for developing diabetes mellitus [8].

Diabetes mellitus could worsen the condition, resulting in further impairment in daily activities of patients with sarcopenia. Unfortunately, treatment of sarcopenia could be challenging. Whether physical exercise could be a therapy for patients with diabetes mellitus and sarcopenia is not known. In this analysis, we aimed to systematically show the impact of exercise intervention as a therapy for patients with diabetes mellitus and sarcopenia.

## METHODS

### Search Databases

Electronic databases, including PubMed, EMBASE, Web of Science and Cochrane database, were searched from November to December 2021 for publications based on exercise intervention in patients with sarcopenia. Reference lists of selective publications were also searched for relevant publications.

### **Search Strategies**

Our search strategies included the following words or phrases:

- Exercise and sarcopenia;
- Exercise intervention and sarcopenia;
- Exercise intervention, diabetes mellitus and sarcopenia;
- Exercise intervention and frail adults;
- Exercise and frail adults;
- Exercise, frail adults and diabetes mellitus;
- Physical exercise and sarcopenia;
- Physical exercise and frail adults.

#### Inclusion and Exclusion Criteria

Studies were included if:

- They were based on exercise intervention in patients with sarcopenia or frail patients [9];
- They also included participants with diabetes mellitus;
- They reported endpoints;
- They were published in English.

Studies were excluded if:

- They were systematic reviews, meta-analyses, or literature reviews;
- They were case studies;
- They did not include patients with diabetes mellitus;
- They were duplicated studies that were repeatedly obtained through different search databases.

### **Outcomes and Exercise Interventions**

The following endpoints were assessed:

- (a) Handgrip strength: defined as the maximum static force that a hand can squeeze;
- (b) Knee extension strength;
- (c) Walking speed;
- (d) Sit-to-stand test: defined as a way to assess an individual's leg strength and endurance by having them stand up from a sitting position repeatedly over the course of 30 s;
- (e) Timed up and go: defined as a test where subjects are asked to rise from a standard armchair, walk to a marker 3 m away, turn, walk back, and sit down again. Timed up and go was reported on the basis of the total time taken to carry out this specific physical activity, and the lesser time taken was considered as a success;
- (f) Leg strength: defined as the ability of your legs to hold a contraction over time.

The outcomes reported in each original study are listed in Table 1.

#### Data Extraction and Quality Assessment

Six authors were involved in the data extraction process. The authors independently extracted data including the authors' names, the

Studies	Outcomes	Exercise intervention	Exercise intervention period	Diagnostic criteria for sarcopenia At least two of the three criteria: (1) modified physical performance test score between 18 and 32, (2) report of difficulty and/or assistance with up to two instrumental activities of daily living and/or one basic activity of daily living, (3) peak aerobic power between 10 and 18 ml/kg/ min		
Binder (2005) [13]	Leg press, knee flexion, knee extension, seated row	Progressive resistance exercise training	3 months			
Brovold (2013) [14]	Physical functioning, mental health, vitality, bodily pain, social functioning, general health, senior fitness test, chair stands, arm curls, back scratch, chair sit- and-reach test, 6-min walk test, physical activity scale for the elderly	High intensity aerobic interval exercise	3 months (to exercise once weekly at home)			
Diaz (2019) [15]	Time to walk 4.6 m, handgrip strength, stand-up-from-chair test	Strength exercise with elastic bands and aerobic exercise	6 months (walking 30 min a day; 5 days per week)	Patients over 70 years of age with a Barthel score > 80 points and a Global Deterioration Scale- Functional Assessment Staging score < 3 points		
Hsieh (2019) [16]	Handgrip strength, 10-m gait speed, upper-body flexibility, lower-body flexibility, lower-extremity strength, geriatrics depression scale	Home-based exercise	6 months	Individuals aged ≥ 65 years of age were invited to participate in this study. Trained case managers screened the frail or pre-frail older adults by using the Cardiovascular Health Study Criteria		
Javier (2021) [17]	Walking, sitting time, vigorous physical activity, moderate physical activity	Power training physical activity	11 weeks			
Kanda (2018) [18]	Timed up and go test, one leg balanced with an open eye, CS-30 count	Low-intensity body weight training,	3 months (once or twice per week)			

### Table 1 Outcomes reported

Studies	Outcomes	Exercise intervention	Exercise intervention period	Diagnostic criteria for sarcopenia		
Kemmler (2010) [19]	Grip strength, trunk extension strength, leg strength, leg power, timed up and go strength, aerobic fitness: time under load	Multipurpose exercise program	18 months	_		
Kim (2012) [20]	Usual walking speed, maximum walking speed, knee extension strength	Physical activity	3 months	Selection based on categorization into one or more of the following inclusion criteria groups: appendicular skeletal muscle mass/height <sup>2</sup> less than 6.42 kg/ m <sup>2</sup> and knee extension strength less than 1.01 Nm/kg, appendicular skeletal muscle mass/height <sup>2</sup> less than 6.42 kg/ m <sup>2</sup> and usual walking speed less than 1.22 m/s, body mass index (BMI) less than 22.0 kg/m <sup>2</sup> and knee extension strength less than 1.01 Nm/kg, and BMI less than 22.0 kg/m <sup>2</sup> and usual walking speed less than 1.22 m/s		
Kim (2016) [21]	Grip strength, knee extension strength, usual walking speed, right step length, right walking angle, left walking angle, stride	Physical activity	3 months	Sarcopenic obesity was operationally defined as body fat percentage of 32% or greater, measured by dual X-ray energy absorptiometry (DXA, Hologic QDR 4500A), combined with skeletal muscle mass index less than 5.67 kg/m <sup>2</sup> ; body fat percent of 32% or greater and grip strength less than 17.0 kg; and body fat percent of 32% or greater and walking speed under 1.0 m/s		
Lai (2021) [22]	Quadriceps femoris muscle strength, 6-min walking test, 30-s sit-to-stand test, 8-foot up-and-go test, daily activity energy expenditure	Lower limb resistance exercise	3 months	-		

### Table 1 continued

Studies	Outcomes	Exercise intervention	Exercise intervention period	Diagnostic criteria for sarcopenia		
Maria (2010) [23]	Ball kick time, kick 8 m, total time kick, gait normal speed, tandem, single leg, balance semi-tandem, rapid gait test, stand up test, Barthel index	Functional circuit training	3 months	-		
Sanchis (2020) [24]	All-cause mortality	Exercise intervention	3 months (three times per week)			
Seino (2017) [25]	Geriatrics depression scale, hand- grip strength, usual gait speed, timed up and go	Resistance exercise	3 months	-		
Suikkanen (2020) [26]	Health-related quality of life	Home-based physical exercise	12 months	_		

 Table 1
 continued

publication year, the type of study, the total number of patients with diabetes mellitus and sarcopenia who were assigned to the exercise intervention group and the control group, and the mean and standard deviation of the endpoints at baseline and during follow-up, preand post-exercise. If any disagreement occurred, it was carefully discussed among all the authors and a consensus was reached.

Quality assessment of the randomized trials was calculated on the basis of the recommendations by the Cochrane collaboration [10], whereas quality assessment of the observational studies was calculated on the basis of the criteria recommended by the Newcastle Ottawa Scale (NOS) [11].

### **Statistical Analysis**

Statistical analysis was carried out by the Rev-Man 5.4 software. Heterogeneity was assessed by the *Q* statistic test, whereas a *P* value less or equal to 0.05 was considered statistically significant. Heterogeneity was also assessed by the  $I^2$  statistic test. A lower  $I^2$  value was considered to represent low heterogeneity, whereas a higher  $I^2$  value was considered to represent higher heterogeneity. A fixed statistical effect was used in this analysis.

Mean and standard deviation were reported in the original studies. The data analysis was represented by weighted mean difference (MD) with 95% confidence intervals (CI). Publication bias was visually represented through funnel plots. In addition, sensitivity analysis was also carried out by an exclusion method, whereas each study was excluded one by one and a new analysis was carried out each time to compare with the main one.

### **Compliance with Ethical Guidelines**

This analysis included data that were previously published. None of the authors carried out experiments on animals or human beings. Therefore, ethical or board review approval was not required for this analysis.

### RESULTS

#### Search Outcomes

The Preferred Reporting Items in Systematic Reviews and Meta-analyses (PRISMA) guideline was followed [12]. Our search resulted in a total of 3128 publications. Over 3000 publications were eliminated after careful assessment of the titles and abstracts since they were not related to the scope of this analysis. Eighty four (84) full-text studies were assessed for eligibility. Following further eliminations based on the inclusion and exclusion criteria, only 14 studies [13–26] were finally included in this analysis. A flow diagram of the study selection is shown in Fig. 1.

#### **General Features of the Studies**

The general features of the studies are listed in Table 2. A total of 431 participants with diabetes mellitus and sarcopenia were included in this meta-analysis. The majority of the studies were randomized trials, whereas only three studies were observational studies. An assessment of the randomized controlled trials with the Cochrane risk assessment tool is demonstrated



Fig. 1 Flow diagram showing the selection of studies to be included in this meta-analysis

in Fig. 2. An assessment of the nonrandomized studies by the NOS was also carried out, and a grade B was allotted to the studies.

#### **Baseline Features of the Studies**

The baseline features are listed in Table 3. The mean age of the participants ranged from 65.3 to 84.1 years. Three studies included only female participants. The percentage of male participants ranged from 0.00% to 74.4%. The percentages of participants with comorbidities including hypertension and those who were smokers are listed in Table 3.

#### Main Results of this Analysis

A statistical analysis was carried out on patients with diabetes mellitus who were assigned to the exercise intervention group. Our analysis showed that the sit-to-stand test and timed up and go were significantly in favor of exercise intervention with MD: -1.57, 95% CI -2.26 to -0.87 (P = 0.0001) and MD -0.61, 95% CI -1.21 to -0.01 (P = 0.05), respectively, as shown in Fig. 3. Handgrip strength (MD 0.56, 95% CI -1.28 to 2.40, P = 0.55), walking speed (MD 79.44, 95% CI 14.06–144.82, P = 0.02), and leg strength (MD 2.41, 95% CI 1.40–3.42, P = 0.00001) were also assessed as shown in Fig. 3.

Another statistical analysis was carried out, this time on patients with diabetes mellitus and sarcopenia who were not assigned to an exercise intervention. The results showed sit-to-stand test (MD 0.41, 95% CI -0.70 to 1.53, P = 0.47), timed up and go (MD -0.10, 95% CI -0.74 to 0.53, P = 0.75), handgrip strength (MD -0.16, 95% CI -3.00 to 2.68, P = 0.91), and leg strength (MD 0.01, 95% CI -1.05 to 1.06, P = 0.99) not to be significantly different, as shown in Fig. 4.

Publication bias was assessed through funnel plot as shown in Fig. 5.

Studies	Type of study	Number of participants in experimental group ( <i>n</i> )	Number of participants in the control group $(n)$
Binder (2005) [13]	RCT	4	4
Brovold (2013) [14]	RCT	8	4
Diaz (2019) [15]	Prospective	44	44
Hsieh (2019) [16]	RCT	39	28
Javier (2021) [17]	Nonrandomized study	21	14
Kanda (2018) [18]	Prospective	7	3
Kemmler (2010) [19]	RCT	10	11
Kim (2012) [20]	RCT	2	2
Kim (2016) [21]	RCT	2	3
Lai (2021) [22]	RCT	5	4
Maria (2010) [23]	RCT	7	6
Sanchis (2020) [24]	RCT	29	38
Seino (2017) [25]	RCT	7	9
Suikkanen (2020) [26]	RCT	31	45
Total number of		216	215

 Table 2 General properties of the studies

RCT Randomized controlled trials

patients (n)



Fig. 2 Graph representing the risk of bias among the randomized trials

Studies	Age (years) Exp/Con	Males (%) Exp/Con	HTN (%) Exp/Con	Smoker (%) Exp/Con	BMI (kg/m²) Exp/Con	Type of DM
Binder (2005) [13]	83.0/83.0	47.0/45.0	53.0/45.0	45.0/47.0	27.0/26.0	NM
Brovold (2013) [14]	77.7/78.3	37.3, 41.1	27.2, 23.2	_	-	T2DM
Diaz (2019) [15]	_	-	-	_	-	T2DM
Hsieh (2019) [16]	72.0/72.5	58.2/63.7	64.6/65.0	_	25.1/25.1	NM
Javier (2021) [17]	74.7/73.1	33.3/42.9	_	_	30.0/28.3	T2DM
Kanda (2018) [18]	80.6/80.4	23.1/19.4	33.8, 38.7	1.50/6.40	_	NM
Kemmler (2010) [19]	68.9/69.2	0.00/0.00	54.4/61.0	3.30/3.30	_	NM
Kim (2012) [20]	79.0/79.2	0.00/0.00	_	_	18.9/18.8	NM
Kim (2016) [21]	81.4/81.2	0.00/0.00	80.0/57.6	_	25.1/25.3	NM
Lai (2021) [22]	65.3/67.6	56.7/50.0	-	_	-	NM
Maria (2010) [23]	83.9/84.1	40.9/36.8	59.1/73.7	_	_	NM
Sanchis (2020) [24]	79.6/80.4	58.0/66.0	89.0/84.0	15.0/18.0	_	NM
Seino (2017) [25]	74.9/74.3	63.2/74.4	52.6/64.1	_	23.3/23.3	NM
Suikkanen (2020) [26]	82.2/82.7	24.0/26.0	73.0/74.0	_	28.4/28.6	NM

Table 3 Baseline features of the studies

*Exp* experimental group, *Con* control group, *HTN* hypertension, *BMI* body mass index, *DM* diabetes mellitus, *T2DM* type 2 diabetes mellitus, *NM* not mentioned

### DISCUSSION

Our analysis showed that physical exercise significantly improved the time taken to stand up from a sitting position and the time taken to stand up and go. However, our results did not show any improvement in handgrip strength, walking speed, or leg strength in these patients with diabetes mellitus.

It has been shown that physical exercise might help to increase muscle strength in older adults, and improve brain volume, including gray and white matter regions, and help frail people to maintain stability while walking, thus preventing falls [4]. Similarly, in our analysis, physical exercise significantly improved the time taken to stand up from a sitting position and the time taken to stand up and go. This assessment was considered successful on the basis of the duration required to carry out those tasks pre- and post-exercise interventions in these patients with diabetes mellitus. Our analysis showed walking speed to significantly favor participants at baseline. However, only two studies were used to assess this outcome, and the level of standard deviation in both studies was high, which might have contributed to this significantly different result supporting patients at baseline.

Physical function usually declines with age, along with the ability to do physical activity. Muscle strength relates to the ability to move and lift objects, and it is measured by the power/force a person can exert and the amount of weight a person can bear or lift. Physical exercise has always contributed to good health. A recent study assessing the effect of homebased physical exercise on days at home in prefrail and frail persons showed exercise intervention to prevent the deterioration of healthrelated quality of life [26]. Another randomized trial demonstrating the effect of resistance exercise on frailty and functional health in community-dwelling older adults showed a

Post exercise			e	B	aseline		Mean Difference		Mean Di	ifference	<b>Risk of Bias</b>
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I IV, Fixe	d, 95% CI	ABCDEFG
1.1.1 Handgrip strength											
Diaz2019	21.1	6.8	44	21.3	6.7	44	2.0%	-0.20 [-3.02, 2.62]	. · · ·	-	
Hsieh2019	26.7	8.7	39	24.5	7.7	39	1.2%	2.20 [-1.45, 5.85]		+	
Kemmler2010	27.7	3.9	10	27.6	4.2	10	1.3%	0.10 [-3.45, 3.65]		+	
Seino2017	30.2	7.8	7	29	7.8	7	0.2%	1.20 [-6.97, 9.37]	-	-	
Subtotal (95% CI)			100			100	4.8%	0.56 [-1.28, 2.40]		<b>•</b>	
Heterogeneity: Chi <sup>2</sup> = 1 Test for overall effect: 2	.14, df = Z = 0.60	3 (P = 0 (P = 0.5	0.77); l <sup>;</sup> 5)	<sup>2</sup> = 0%							
1.1.2 waiking speed											
Brovold2013	486.4	111.1	8	451.3	111.1	8	0.0%	35.10 [-73.78, 143.98]			•
Lai2021	653.18	56.79	5	548.74	74	5	0.0%	104.44 [22.68, 186.20]			
Subtotal (95% CI)			13			15	0.0%	/9.44 [14.00, 144.02]			
Heterogeneity: Chi <sup>2</sup> = 1 Test for overall effect: 2	2 = 2.38	1 (P = 0.0)	2) 2)	<sup>2</sup> = 0%							
1.1.3 Sit to stand test											
Brovold2013	8	3.7	8	9.7	3.7	8	1.2%	-1.70 [-5.33, 1.93]	-	-	
Diaz2019	15.9	11.6	44	16.6	8.3	44	0.9%	-0.70 [-4.91, 3.51]	-	-	
Lai2021	17.21	3.95	5	12.87	3.31	5	0.8%	4.34 [-0.18, 8.86]		-	
Maria2010	17.81	0.68	7	19.55	0.71	7	30.7%	-1.74 [-2.47, -1.01]			
Subtotal (95% CI)			64			64	33.7%	-1.57 [-2.26, -0.87]			
Heterogeneity: Chi <sup>2</sup> = 6	.95. df =	3(P = 0)	).07): I	² = 57%							
Test for overall effect: 2	<u>z</u> = 4.41	(P < 0.0	001)								
1.1.4 Time up and go											
Brovold2013	6.6	2.2	8	7	2.2	8	3.5%	-0.40 [-2.56, 1.76]		t	
Kanda2018	13.7	5.7	7	14.7	6.4	7	0.4%	-1.00 [-7.35, 5.35]	-	+	
Kemmler2010	7.3	1.04	10	7.66	1.09	10	18.7%	-0.36 [-1.29, 0.57]		•	
Lai2021	4.71	0.8	5	5.8	0.83	5	16.0%	-1.09 [-2.10, -0.08]			
Seino2017	5.77	1.3	7	6.04	1.6	7	7.0%	-0.27 [-1.80, 1.26]		t	
Subtotal (95% CI)			37			37	45.6%	-0.61 [-1.21, -0.01]			
Heterogeneity: Chi <sup>2</sup> = 1	.38, df =	4(P = 0)	0.85); l <sup>a</sup>	² = 0%							
Test for overall effect. 2	2 - 2.00	(P = 0.0	5)								
1.1.5 Leg strength							0.001				
Hsieh2019	6.9	6.7	39	3.9	5.2	39	2.3%	3.00 [0.34, 5.66]	_		
Kemmler2010	81.4	19.9	10	71.69	18.15	10	0.1%	9.71 [-6.98, 26.40]	-		
Lai2021	8.04	0.96	5	5.76	0.8	5	13.6%	2.28 [1.18, 3.38]			
Subtotal (95% CI)	00.11	0 (D )	54	0.00/		54	15.9%	2.41 [1.40, 3.42]			
Heterogeneity: Chi <sup>2</sup> = 0	98, df =	2(P = 0)	).61); I	<sup>2</sup> = 0%							
l est for overall effect: 2	2 = 4.67	(P < 0.0	0001)								
Total (95% CI)			268			268	100.0%	-0.39 [-0.79, 0.01]			
Heterogeneity: Chi <sup>2</sup> = 5	9.20, df	= 17 (P	< 0.00	001); l² =	71%				-100 -50	0 50 10	
Test for overall effect: 2	z = 1.90	(P = 0.0	6)						Favours [post exercise]	Favours [baseline]	•
Test for subgroup differ	rences: C	Chi² = 47	.75, df	= 4 (P <	0.0000	1),  ² =	91.6%				
Risk of bias legend											
(A) Random sequence	generati	on (sele	ction b	ias)							
(B) Allocation concealm	nent (sele	ection bi	as)								
(C) Blinding of participa	ints and	personn	el (per	formance	e bias)						
(D) Blinding of outcome	assessi	ment (de	etection	n bias)							
(E) Incomplete outcome	e data (a	ttrition b	ias)								
(F) Selective reporting (	reporting	g bias)									
((G) ()ther blas											

Fig. 3 Progress in the exercise intervention group at baseline compared with follow-up in patients with diabetes mellitus and sarcopenia

3-month multifactorial intervention to have reduced frailty and improved functional health, and these effects persisted for at least 3 more months after the exercise intervention [25].

Moreover, a prospective observational study involving 97 elderly men and women aged 65 years and older showed that low-intensity body weight training with slow movement on motor function resulted in improvements in ambulatory function and lower limb muscle strength within a short time [18].

In a narrative review, based on the 14 studies focusing on the effects of physical activity

interventions in frail and pre-frail communitydwelling people on frailty status, muscle strength, physical performance, and muscle mass, the authors concluded and supported the fact that physical exercise intervention has been effective at reducing frailty and increasing muscle strength and physical performance [27]. Resistance training has shown to be an effective way of increasing muscle mass and strength regardless of protein supplementation, leading to improvement in activities such as bench press and walking speed, as demonstrated by a recent study carried out by Maltais et al. based

	Fo	llow u	р	Ba	aseline			Mean Difference	Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I IV, Fixed, 95% CI	ABCDEFG
1.2.1 Handgrip stren	igth									
Hsieh2019	25.3	7.7	28	25	7.8	28	1.4%	0.30 [-3.76, 4.36]	+	
Kemmler2010	26.4	4.7	11	27	4.8	11	1.5%	-0.60 [-4.57, 3.37]	+	
Subtotal (95% CI)			39			39	2.9%	-0.16 [-3.00, 2.68]	•	
Heterogeneity: Chi <sup>2</sup> =	0.10, df	= 1 (P	= 0.76)	; $I^2 = 0$	%					
Test for overall effect	: Z = 0.11	1 (P = 0	.91)							
1.2.3 Sit to stand Te	st									
Lai2021	13 43	4 22	4	13 16	41	4	0.7%	0 27 [-5 50 6 04]	+	
Maria2010	17 47	1.08	6	17.05	0.93	6	17.8%	0.42 [-0.72, 1.56]	+	
Subtotal (95% CI)			10		0.00	10	18.5%	0.41 [-0.70, 1.53]	•	
Heterogeneity: Chi <sup>2</sup> =	0.00, df	= 1 (P	= 0.96)	; l <sup>2</sup> = 0%	%					
Test for overall effect	Z = 0.73	3 (P = 0	.47)							
1.2.4 Time up and ge	D									
Kanda2018	13.7	5.7	3	14.7	6.4	3	0.2%	-1.00 [-10.70, 8.70]		
Kemmler2010	7.6	1.24	11	7.51	1.19	11	22.5%	0.09 [-0.93, 1.11]	I	
Lai2021 Subtotal (95% CI)	5.29	0.67	4	5.51	0.49	4	35.0%	-0.22 [-1.03, 0.59]	T	
Hotorogonoity: Chi <sup>2</sup> =	0.25 df	- 2 (D	- 0.00)	. 12 - 00	/	10	57.070	-0.10 [-0.74, 0.33]		
Test for overall effect	7 = 0.33	-2(P)	- 0.00) 175)	, I <sup>_</sup> = 05	/0					
rest for overall effect	. 2 - 0.02	- (1 - 0	.13)							
1.2.5 Leg strength										
Hsieh2019	1.7	2.9	28	1.6	3	28	9.7%	0.10 [-1.45, 1.65]	+	
Lai2021	6.04	0.92	4	6.11	1.15	4	11.1%	-0.07 [-1.51, 1.37]	t	
Subtotal (95% CI)			32			32	20.8%	0.01 [-1.05, 1.06]		
Heterogeneity: Chi <sup>2</sup> =	0.02, df	= 1 (P	= 0.87)	$  ^2 = 0$	%					
Test for overall effect	: Z = 0.02	2 (P = 0	.99)							
Total (95% CI)			99			99	100.0%	0.01 [-0.47. 0.50]		
Heterogeneity: Chi <sup>2</sup> =	1.01. df	= 8 (P	= 1.00)	$ ^{2} = 0^{9}$	%					1
Test for overall effect	Z = 0.06	5 (P = 0	.95)	,					-100 -50 0 50 100	
Test for subgroup diff	erences:	Chi <sup>2</sup> =	0.64, 0	lf = 3 (F	9 = 0.8	9),  ² =	0%		Favours [Follow up] Favours [Baseline]	
Risk of bias legend										
(A) Random sequenc	e genera	ition (se	election	i bias)						
(B) Allocation concea	Iment (se	election	bias)							
(C) Blinding of particip	pants and	d perso	nnel (p	erforma	ance bi	as)				
(D) Blinding of outcom	ne asses	sment	(detect	ion bias	5)					
(E) Incomplete outcor	ne data (	attritior	n bias)							
(F) Selective reporting	g (reporti	ng bias	)							
(G) Other bias										

Fig. 4 Comparing the outcomes at baseline versus follow-up in patients with diabetes mellitus and sarcopenia in the absence of exercise intervention (control group)

on elderly men with sarcopenia [28]. However, the percentage or number of participants with diabetes mellitus was not given. In another study, a randomized trial, focusing on the optimal frequency/time combination of wholebody vibration training for improving muscle size and strength of 80 people with age-related muscle loss (sarcopenia), the authors showed that vibration training exercise improved and maintained knee extension performance during a 12-week follow-up time period, further supporting the benefits of exercise intervention in patients with sarcopenia [29].

Even though our results showed no improvement in handgrip strength, walking speed, or leg strength in these patients with diabetes mellitus, the very low number of participants, different criteria for defining sarcopenia, the inclusion of frail participants, a low number of studies assessing the respective outcomes, and missing information (duration of diabetes mellitus, glycemic control, racial status of the participants) may explain this result.

#### Limitations

Our study has several limitations. First of all, a limited number of original studies based on this idea were published. Therefore, retrieving participants with diabetes mellitus led to a low number of participants for this analysis. Secondly, although we included many relevant publications in this analysis, those with outcomes reported in percentages instead of seconds could not be included in statistical analysis. Another limitation was the fact that the follow-up time periods from baseline varied



Fig. 5 Funnel plot showing publication bias

across studies. The duration of intervention was therefore not taken into consideration in this analysis. Moreover, we could not use data from all of the relevant studies because few studies reported outcomes that were unique and not reported in other studies for comparison. Hence, even though included in this study, we could not use their data for statistical analysis. In addition, among those studies included in this analysis, the diagnostic criteria for sarcopenia were unclear in some of the studies, which could have had an impact on the results of this analysis. We have also included both patients with sarcopenia and those with frailty in this analysis, which could also affect have affected the results of this analysis. Physical function impairment is common in both sarcopenia and frailty, and these two conditions are highly similar and have therefore not yet received a unique operational definition. Therefore, we included frail patients with diabetes mellitus and patients with diabetes mellitus and sarcopenia in this analysis. Another limitation could be that exercise frequency per week and intensity of exercise were not taken into consideration since these data were not regularly reported in the original studies. Also, as endpoints including skeletal muscle mass, skeletal muscle mass index, and lean body mass were not reported in most of the original studies, we could not assess these outcomes in our analysis. In addition, features such as duration of diabetes mellitus, glycosylated hemoglobin (HbA1c), patients with micro- and macrovascular complications, number of patients on insulin therapy, and number of patients on oral hypoglycemic drugs were not reported, and were therefore ignored in this analysis. Even though racial differences could have had an impact on the outcomes, for example, body mass index of the Asian population was lower compared with people from Western countries, we could not conduct this comparison in our analysis, demonstrating another limitation of this study.

### CONCLUSION

Exercise intervention significantly improved the time taken to stand up from a sitting

position, and to "stand up and go" in patients with diabetes mellitus and sarcopenia. Therefore, exercise intervention should be considered a relevant therapy for such patients. Further research with a larger population of participants with diabetes mellitus and sarcopenia is required to confirm our hypothesis.

## ACKNOWLEDGEMENTS

*Funding.* No external funding or sponsorship was received for this study or publication of this article. This study was funded by the authors.

*Authorship.* All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

*Author Contributions.* The authors Siyao Gao, Ling Yu, Guozhong Yi, Tong Li, Zhenyin Chen, and Jiawang Ding were responsible for the conception and design, acquisition of data, analysis and interpretation of data, drafting the initial manuscript and revising it critically for important intellectual content. All the authors approved the final manuscript as it is.

*Disclosures.* The authors Siyao Gao, Ling Yu, Guozhong Yi, Tong Li, Zhenyin Chen, and Jiawang Ding declare that they have no competing interests.

*Compliance with Ethics Guidelines.* This meta-analysis is based on previously conducted studies and does not contain any new study with human participants or animals performed by any of the authors.

**Data Availability.** All data generated or analyzed during this study are included in this published article. References of the original papers involving the data source which have been used in this paper have been listed in the main text of this current manuscript. All data are publicly available in electronic databases.

Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source. provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/bync/4.0/.

# REFERENCES

- 1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Aihie Sayer A, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWG-SOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601.
- Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel J-P, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M, European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23.
- 3. Nishimura T, Imai A, Fujimoto M, Kurihara T, Kagawa K, Nagata T, Sanada K. Adverse effects of the coexistence of locomotive syndrome and sarcopenia on the walking ability and performance of activities of daily living in Japanese elderly females: a cross-sectional study. J Phys Ther Sci. 2020;32(3): 227–32.

- 4. Von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cach Sarcop Muscle. 2010;1(2): 129–33.
- 5. Nascimento CM, Ingles M, Salvador-Pascual A, Cominetti MR, Gomez-Cabrera MC, Viña J. Sarcopenia, frailty and their prevention by exercise. Free Radic Biol Med. 2019;20(132):42–9.
- 6. Scott D, de Courten B, Ebeling PR. Sarcopenia: a potential cause and consequence of type 2 diabetes in Australia's ageing population? Med J Aust. 2016;205(7):329–33.
- Wang T, Feng X, Zhou J, Gong H, Xia S, Qing Wei XuHu, Tao R, Li L, Qian F, Li Yu. Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly. Sci Rep. 2016;6:38937.
- Velázquez-Alva MC, Irigoyen-Camacho ME, Zepeda-Zepeda MA, Lazarevich I, Arrieta-Cruz I, D'Hyver C. Sarcopenia, nutritional status and type 2 diabetes mellitus: a cross-sectional study in a group of Mexican women residing in a nursing home. Nutr Diet. 2020;77(5):515–22.
- 9. Landi F, Calvani R, Cesari M, Tosato M, Martone AM, Bernabei R, Onder G, Marzetti E. Sarcopenia as the biological substrate of physical frailty. Clin Geriat Med. 2015;31(3):367–74.
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group. Cochrane statistical methods group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;18(343):d5928.
- 11. Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
- 12. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;6(7):e1000100.
- 13. Binder EF, Yarasheski KE, Steger-May K, Sinacore DR, Brown M, Schechtman KB, Holloszy JO. Effects of progressive resistance training on body composition in frail older adults: results of a randomized, controlled trial. J Gerontol Ser A Biol Sci Med Sci. 2005;60(11):1425–31.
- 14. Brovold T, Skelton DA, Bergland A. Older adults recently discharged from the hospital: effect of

aerobic interval exercise on health-related quality of life, physical fitness, and physical activity. J Am Geriat Soc. 2013;61(9):1580–5.

- 15. Díaz EG, Ramírez JA, Fernández NH, Gallego CP, Hernández DD. Effect of strength exercise with elastic bands and aerobic exercise in the treatment of frailty of the elderly patient with type 2 diabetes mellitus. Endocrinología, Diabetes y Nutrición (English ed.). 2019;66(9):563-70.
- 16. Hsieh T-J, Shin-Chang Su, Chen C-W, Kang Y-W, Ming-Hsia Hu, Hsu L-L, Szu-Yun Wu, Chen L, Chang H-Y, Chuang S-Y, Pan W-H, Hsu C-C. Individualized home-based exercise and nutrition interventions improve frailty in older adults: a randomized controlled trial. Int J Behav Nutr Phys Act. 2019;16(1):119.
- 17. Brazo-Sayavera J, López-Torres O, Martos-Bermúdez Á, Rodriguez-Garcia L, González-Gross M, Guadalupe-Grau A. Effects of power training on physical activity, sitting time, disability, and quality of life in older patients with type 2 diabetes during the COVID-19 confinement. effects of power training on physical activity, sitting time, disability, and quality of life in older patients with type 2 diabetes during the COVID-19 confinement. J Phys Act Health. 2021;18(6):660–68.
- 18. Kanda K, Yoda T, Suzuki H, Okabe Y, Mori Y, Yamasaki K, Kitano H, Kanda A, Hirao T. Effects of low-intensity bodyweight training with slow movement on motor function in frail elderly patients: a prospective observational study. Environ Health Prev Med. 2018;23(1):4.
- 19. Kemmler W, von Stengel S, Engelke K, Häberle L, Mayhew JL, Kalender WA. Exercise, body composition, and functional ability: a randomized controlled trial. Am J Prevent Med. 2010;38(3):279–87.
- 20. Kim HK, Suzuki T, Saito K, Yoshida H, Kobayashi H, Kato H, Katayama M. Effects of exercise and amino acid supplementation on body composition and physical function in community-dwelling elderly Japanese sarcopenic women: a randomized controlled trial. J Am Geriat Soc. 2012;60(1):16–23.
- 21. Kim H, Kim M, Kojima N, Fujino K, Hosoi E, Kobayashi H, Somekawa S, Niki Y, Yamashiro Y, Yoshida H. Exercise and nutritional supplementation on community-dwelling elderly Japanese women with sarcopenic obesity: a randomized controlled trial. J Am Med Dir Assoc. 2016;17(11): 1011–9.
- 22. Lai X, Bo L, Zhu H, Chen B, Zhao W, Hongdi D, Huo X. Effects of lower limb resistance exercise on muscle strength, physical fitness, and metabolism in pre-frail elderly patients: a randomized controlled trial. BMC Geriatr. 2021;21(1):447.

- 23. Giné-Garriga M, Guerra M, Pagès E, Manini TM, Jiménez R, Unnithan VB. The effect of functional circuit training on physical frailty in frail older adults: a randomized controlled trial. J Aging Phys Act. 2010;18(4):401–24.
- 24. Sanchis J, Sastre C, Ruescas A, Ruiz V, Valero E, Bonanad C, García-Blas S, Fernández-Cisnal A, González J, Miñana G, Núñez J. Randomized comparison of exercise intervention versus usual care in older adult patients with frailty after acute myocardial infarction. Am J Med. 2021;134(3):383-390.e2.
- 25. Seino S, Nishi M, Murayama H, Narita M, Yuri Yokoyama Yu, Taniguchi NY, Amano H, Kitamura A, Shinkai S. Effects of a multifactorial intervention comprising resistance exercise, nutritional and psychosocial programs on frailty and functional health in community-dwelling older adults: a randomized, controlled, cross-over trial. Geriatr Gerontol Int. 2017;17(11):2034–45.
- 26. Suikkanen SA, Soukkio PK, Aartolahti EM, Kautiainen H, Kääriä SM, Hupli MT, Sipilä S, Pitkälä KH,

Kukkonen-Harjula KT. Effects of home-based physical exercise on days at home and cost-effectiveness in pre-frail and frail persons: randomized controlled trial. J Am Med Direct Assoc. 2021;22(4):773–9.

- 27. Haider S, Grabovac I, Dorner TE. Effects of physical activity interventions in frail and prefrail community-dwelling people on frailty status, muscle strength, physical performance and muscle mass—a narrative review. Wiener Klinische Wochenschrift. 2019;131(11):244–54.
- 28. Maltais ML, Ladouceur JP, Dionne IJ. The effect of resistance training and different sources of postexercise protein supplementation on muscle mass and physical capacity in sarcopenic elderly men. J Strength Condit Res. 2016;30(6):1680–7.
- 29. Wei N, Pang MY, Ng SS, Ng GY. Optimal frequency/time combination of whole-body vibration training for improving muscle size and strength of people with age-related muscle loss (sarcopenia): a randomized controlled trial. Geriat Gerontol Int. 2017;17(10):1412–20.